Of the other 824 patients, who had neither ETV6-RUNX1-positive ALL nor hyperdiploidy ALL, 170 received one dose of daunorubicin, and 654 received two doses. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.